Recommendations statement on the immunosuppressive treatment of non-infectious, non-neoplastic, non-anterior uveitis

Espinosa, Gerard; Herreras, J.M.; Morales, José María García Ruiz de; Cordero‐Coma, Miguel

doi:10.1016/j.medcle.2019.10.009

Cited by 2 publications

(2 citation statements)

References 121 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, the most used drug was MTX (55.4%), followed by CyA (16.6%), in agreement with other studies, in which MTX was considered a drug with good response and low cost [26,29,31]. Compared to MFM, both have a high success rate [22,30], 63% and 64%, respectively, although in our case, MMF was used on seven occasions, and it required a change in treatment due to a lack of response in six of them (85.71%): three patients with intermediate uveitis, two with birdshot uveitis, and one with idiopathic RAAU.…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

An Observational Study in the Real Clinical Practice of the Treatment of Noninfectious Uveitis

Esteban-Ortega,

Steiner,

Andreu-Vázquez

et al. 2024

JCM

View full text Add to dashboard Cite

Background: The aim of this study was to describe the characteristics of patients with uveitis associated with an immunologic or idiopathic disease that requires immunosuppressive treatment and the response to such treatments in real clinical practice. Methods: An observational, descriptive, longitudinal, and retrospective study of a cohort of patients diagnosed with noninfectious uveitis was performed. To assess the response to treatment, we evaluated the change in visual acuity, vitritis, and the presence of macular edema. Results: We included 356 patients. Overall, 12% required treatment with systemic corticosteroids, and 66 patients (18.5%) required immunosuppressive/biological treatment, with methotrexate being the most used (55%). Immunosuppressive drugs were used in 59 cases (in 56 patients, as the first choice of treatment and for 3 patients as the second choice after treatment with biologics). Treatment with biologics was the first choice in 10 patients out of 66 (15%), and 34 (48%) required them at some time during the disease, with adalimumab being the most commonly used. Thirty-five patients (53%) needed to switch drugs due to a lack of response to the first one. There were no differences between different drugs in the resolution of vitritis and improvement in vision. Conclusions: The use of systemic corticosteroids and immunosuppressive/biologics was necessary for a high number of patients with noninfectious uveitis. In our series, tocilizumab was significantly more effective in the resolution of macular edema.

show abstract

Section: Discussionsupporting

confidence: 90%

“…Systemic treatment was used in severe cases with poor response to topical treatment or with a high number of recurrences. For the decision on immunosuppressive therapy, we followed the recommendations of the Spanish Society of Ocular Inflammation [ 21 , 22 ].…”

Section: Methodsmentioning

confidence: 99%

An Observational Study in the Real Clinical Practice of the Treatment of Noninfectious Uveitis

Esteban-Ortega,

Steiner,

Andreu-Vázquez

et al. 2024

JCM

View full text Add to dashboard Cite

show abstract

Observational Study in Real Clinical Practice of the Treatment of Non-Infectious Uveitis

Esteban-Ortega,

Steiner,

Andreu-Vázquez

et al. 2024

Preprint

View full text Add to dashboard Cite

To describe the characteristics of patients with uveitis associated with an immunologic or idio-pathic disease that requires immunosuppressive treatment and the response to such treatments in real clinical practice. Observational, descriptive, longitudinal, and retrospective study of a cohort of patients diagnosed with idiopathic uveitis or autoimmune disease-related uveitis. To assess the response to treatment we have evaluated the change in visual acuity and vitritis and the presence of macular edema. We included 356 patients. Twelve percent required treatment with systemic corticosteroids and 66 patients (18.5%) immunosuppressive/biological treatment, with metho-trexate being the most used (55%). Immunosuppressive drugs were used in 59 cases the least re-sponsive being mycophenolate mofetil. Ten patients of the 66 (15%) started treatment with bio-logics. Thirty-five patients (53%) needed to switch drugs due to a lack of response to the first one. There were no differences between different drugs in the resolution of vitritis and improvement of vision. The disappearance of macular edema was achieved in all patients treated with tocilizumab. The use of systemic corticosteroids and Immunosuppressive/biologics was necessary for a high number of patients with non-infectious uveitis. In our series tocilizumab was significantly more effective in the resolution of macular edema.

show abstract

Recommendations statement on the immunosuppressive treatment of non-infectious, non-neoplastic, non-anterior uveitis

Cited by 2 publications

References 121 publications

An Observational Study in the Real Clinical Practice of the Treatment of Noninfectious Uveitis

An Observational Study in the Real Clinical Practice of the Treatment of Noninfectious Uveitis

Observational Study in Real Clinical Practice of the Treatment of Non-Infectious Uveitis

Contact Info

Product

Resources

About